Carly P. Smith, PhD and Daniel R. George, PhD, MSc
Invisibility of racial inequity and gender inclusion in clinical research means key features of disease etiology and symptom presentation are unaccounted for.
AMA J Ethics. 2021;23(7):E563-568. doi:
10.1001/amajethics.2021.563.
Charles E. Binkley, MD, Michael S. Politz, MA, and Brian P. Green, PhD
If the safe-and-effective standard for judging devices’ potential as therapy or enhancement is inadequate, one might wonder whether BCI regulation should be overseen by the FDA.
AMA J Ethics. 2021;23(9):E745-749. doi:
10.1001/amajethics.2021.745.
Dr Charles Binkley joins Ethics Talk to discuss his article, coauthored with Michael Politz and Dr Brian Green: "Who, If Not the FDA, Should Regulate Implantable Brain-Computer Interface Devices?"
Zareen Zaidi, MD, PhD, Daniele Ölveczky, MD, MS, Nicole A. Perez, PhD, Paolo C. Martin, PhD, Andres Fernandez, MD, MSEd, Philicia Duncan, MD, and Hannah L. Anderson, MBA
This article canvasses ways to help trainees cultivate discernment and action in response to inequity.
AMA J Ethics. 2024;26(1):E12-20. doi:
10.1001/amajethics.2024.12.
This article proposes which instructional design priorities should guide development of inclusive, accessible online curricula and learning experiences.
AMA J Ethics. 2024;26(1):E26-35. doi:
10.1001/amajethics.2024.26.
Whitney V. Cabey, MD, MSHP, MA, Nicolle K. Strand, JD, MBE, MPH, and Erin Marshall, MSS, LSW
An emerging and important goal of health professions training is to develop a workforce equipped to address structural determinants of patients’ health.
AMA J Ethics. 2024;26(1):E48-53. doi:
10.1001/amajethics.2024.48.